We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Immupharma Plc | LSE:IMM | London | Ordinary Share | GB0033711010 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.055 | -2.52% | 2.125 | 2.05 | 2.20 | 2.25 | 2.10 | 2.20 | 2,365,381 | 16:35:02 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -3.81M | -0.0114 | -1.89 | 7.17M |
Date | Subject | Author | Discuss |
---|---|---|---|
10/12/2017 21:12 | Jpleight: expect a rant about the deal on the table. I a agree with you, subject to results a deal will be done.The challenge is that P140 has moved from being a point solution for lupus. To be a drug that can reduce immune reactions in wider diseases, not a cure, but a combination treatment.if successful is has more legs and arms to it, especially with the Safety profile. | l0ngterm | |
10/12/2017 21:06 | Asat, thank you for your insight from the london meeting, that seems to me as very very significant. I knew that doctors and patients would know but wasnt aware Tim refered to that in the meeting. That together with the issue of options...seems to me there is a good deal on the table already conditional to a significant p value. hold or derisk...first world problems... | jpleight | |
10/12/2017 20:17 | Surprised no press after Fridays move up, well I haven’t seen any so far? | ny boy | |
10/12/2017 20:10 | There will have been drop outs, there always are. | asat91 | |
10/12/2017 20:09 | I thought it was general agreed from past RNS s that we know nothing about the drop out rate, if indeed there have been any drop outs. | divmad | |
10/12/2017 20:04 | At the most recent presentation in London/Mayfair someone asked a pretty brainless question asking what the drop out rate is in the lupuzor group (which obviously no-one knows as everyone is blind). Anyway Tim went on to say that 'everything looks good, the patients are "happy", the doctors are "happy", and I'm "happy". Everyone involved is "happy"'. He was communicating that it is clear to him, doctors, and patients who is in the lupuzor group and who is in the placebo group because the efficacy has been so consistently strong with some patients (lupuzor group) whereas others (in the placebo group) have dropped out + had no/minimal improvement. He obviously couldn't explicitly say that - he needs to protect himself just in case! Did anyone else who went to the presentation get the same impression that this is what he was trying to say? If it is that obvious phenotypically to the naked eye that there is improvement then the statistical results are likely to be highly efficacious. | asat91 | |
10/12/2017 20:03 | Mr t, I quizzed the company a couple of weeks back about dates for anouncements for the end of trial/results and they suggested they would announce end of trial early in the new year and top line results some time later in q1. I didn't ask about December. They may release something but I don't see that they need to. | homebrewruss | |
10/12/2017 19:47 | Agreed the investor presentations filled me with confidence .But saying that the company is superbly run like clockwork , I have to say this is the first xmas in years in share tradeing i feel so positive going into a new year ,If this comes of there will be a lot of happy folks out there .I bet a lot of people are weighting up what to do hold to the results or derisk , Thats the 64 million dollar question .Myself im holding as have a very nice average .I would like to buy more next week but i will see the price action first , However my 1.50 will be broken and hopefully two pound will be on the horizon .Good luck all whatever you decide | scoredagain | |
10/12/2017 19:43 | Thanks all v interesting....I reckon doctors and others must be able to see the difference in patients no? Anyway, let's see where share price ends up this week to see if my theory has any effacy haha... Gla | qs99 | |
10/12/2017 19:28 | And if it does pass then its a £60 to £100 share. Happy days. Tim McC said it would be a multi-billion $ drug. Tim is the one who has all the inside information. | money maker1 | |
10/12/2017 19:19 | Agreed the investor presentations were excellent. | blackbear | |
10/12/2017 18:43 | Tim seemed to emphasize in the 45min video that IMM wanted to ensure that investors were always kept in the loop - no surprises - I think if there was any issues that cropped up over the past 12 months then this would have communicated. It takes a long time to build up investors confidence and easy to lose it so smoke and mirrors isn't their game I believe. It would achieve nothing. GLA. | hamhamham1 | |
10/12/2017 18:33 | It’s not a 50/50 bet really, I would say based on data and progress released from the Company so far, it’s more like 70/30 imho | ny boy | |
10/12/2017 18:05 | Definitely not - a binary bet that can go either of 2 ways certainly has no implication that either outcome is equally probable. In some cases like the toss of a coin then yes it does but not all cases are like that. | spawny100 | |
10/12/2017 17:59 | If there are only two outcomes it still doesn't mean that each outcome has an equal 50-50 chance? | hamhamham1 | |
10/12/2017 17:46 | QS we have already established the Lupuzor Phase 3 outcome is not a binary 50/50 bet. With Lupuzor we have the benefit of superb best ever for lupus Phase 2b results, and ongoing excellent safety and tolerability in Phase 3 - both factors beating Benlysta; plus the benefit of selective mode of action, competitive price and high gross margin. All this puts the odds very firmly in Lupuzor's favour. I personally consider Lupuzor has a 95%+ probability of reaching the market. | hottingup | |
10/12/2017 17:44 | homebrewuss, NY Boy, thanks for your comments. In the interim results from the end of September IMM said: “We are focused on the late stage clinical development of Lupuzor™ through its pivotal Phase III trial and are looking forward with confidence to announcing top-line data by the end of the first quarter of 2018. We will also continue to communicate on a regular basis with shareholders as this trial progresses.” Which suggests the company will give an update this year or early next year before top line results are finalised. IMM did publish an announcement on 22 Dec last year so it’s possible they could do something in December this year if they felt it necessary. However, it’s not clear to me what they would have worth announcing this year. | mr. t | |
10/12/2017 16:39 | I'm not expecting any news flow until after the new year, doubt they will release news flow, now that the Christmas office party season has kicked off. | ny boy | |
10/12/2017 15:15 | from experience in other trial I personally talked to doctors involved and they obviously spot the improvement in the patients; they also know how many patients drop out; They have a very good idea of how things are going, may be that info leaked? Be optimistic but de risk your position. | jpleight | |
10/12/2017 15:08 | Mr T, they will announce that all patients have completed the trial in early Jan and possibly something sooner to say all patients have had their last dose. | homebrewruss | |
10/12/2017 14:26 | QS99. Even though the test is blind so that you don't know who is using the drug and who is using the placebo, you still get an indication that it may be working if a good percentage of people are getting better (efacecy ticked) and equally not dropping out (no side effects ticked)? | hamhamham1 | |
10/12/2017 14:19 | yup, agreed mate. Time will tell as we approach 2018, where will the market let the valuation "settle" as it were without news? Some of the valuations being bandied around on here brings a tear to your eye! | qs99 | |
10/12/2017 14:07 | I guess the "no news is good news" mentality QS99 - the nearer the trial is to completion with no adverse news then the more likely people consider it will be a success? So people pile in not wanting to miss the boat. That's how I see it anyway. | spawny100 | |
10/12/2017 14:02 | Friday's march North IMO is a sign of good momentum into this week an beyond. Possibly still a binary investment and yes the entire tests are supposed to be "blind" but I just cannot still help thinking that if this say doubled between now and early 18 (why not?) then it may be that people are aware of good news coming.....why else would it keep going other than gamblers taking a 50-50 bet? DYOR etc | qs99 | |
10/12/2017 13:48 | I particularly liked the last sentence NY Boy: "this is a very attractive asset for a lot of companies in the pharmaceutical industry so yes, we are getting a lot of interest on it." | top tips |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions